Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.